Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer

(2013) J. R. Brahmer et al.   Cancer Immunology Research

Evolution of end points for cancer immunotherapy trials

(2012) A. Hoos   ANNALS OF ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

(2011) Zahra Hanaizi et al.   EUROPEAN JOURNAL OF CANCER

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

(2010) Frank R. Brennan et al.   mAbs

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

(2010) Axel Hoos et al.   SEMINARS IN ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY